Edgewise Therapeutics (EWTX) Cash from Operations (2020 - 2026)

Edgewise Therapeutics has disclosed Cash from Operations across 7 years of filings, most recently posting 42543000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 42543000.0, down 12.35% year-over-year; the trailing twelve-month figure through Mar 2026 was 148493000.0 (down 25.53% YoY), and the FY2025 annual result was 143816000.0, down 31.91% from the prior year.
• Cash from Operations came in at 42543000.0 for Q1 2026 at Edgewise Therapeutics, down from 38592000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 11855000.0 in Q4 2022 to a low of 42543000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 26830000.0 (2023), against an average of 25880588.24.
• Across the five-year window, Cash from Operations slumped 126.32% in 2023 and declined 0.47% in 2024, its largest moves.
• Edgewise Therapeutics' Cash from Operations stood at 11855000.0 in 2022, then plunged by 126.32% to 26830000.0 in 2023, then dropped by 0.47% to 26957000.0 in 2024, then plunged by 43.16% to 38592000.0 in 2025, then declined by 10.24% to 42543000.0 in 2026.
• The last three Cash from Operations figures came in at 42543000.0 (Q1 2026), 38592000.0 (Q4 2025), and 34776000.0 (Q3 2025), per Business Quant data.